Article

Samuel Chey, MPH: Identifying SID in Patients with IBS-D

Author(s):

Sucrase isomaltase deficiency is often overlooked symptom in adult patients with IBS-D.

A new study presented at the 2021 Digestive Disease Week (DDW) Virtual Meeting found that sucrase isomaltase deficiency (SID) may be an overlooked cause for symptoms in patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).

Data in the study identified SID in nearly 1 in 10 patients with IBS-D or functional diarrhea, where patients reported unhappiness with bowel habits, gastrointestinal distress, and interference in their daily lives.

In an interview with HCPLive, Samuel Chey, MPH, Michigan Medicine, spoke on the results of the interim analysis, as well as further research his team is hoping to explore on the ability to easier identify patients with SID.

“One thing that our team is interested in pursuing further, after we get past the final validation with a larger subset in this particular avenue, is also to evaluate the efficacy in some of the secondary alternative diagnosis methods that exist for the condition,” Chey said.

He noted that SID is generally thought of by most gastroenterologists as a congenital pediatric condition, rather than in adults, which may lead SID to be an overlooked symptom in treatment of IBS-D.

Chey also spoke on the future of treating SID in patients with IBS-D.

“If the data we are seeing as part of this interim analysis is true, that this large portion of patients that have IBS that also concurrently have SID, there is definitely an interest in pursuing this further, develop new therapies, develop new approaches to relieve their symptoms, and we are definitely seeing patient demand for it,” Chey said.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Malin Fromme, MD | Credit: RWTH Aachen
Pavel Strnad, MD | Credit: AASLD
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Gideon Hirschfield, FRCP, PhD | Credit: UHN Foundation
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
Country-Level Socioeconomic Status, Healthcare Impact AKI Outcomes in Cirrhosis
© 2024 MJH Life Sciences

All rights reserved.